



# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Meeting #2

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

June 28, 2023





# Call to Order/Roll Call

Mike Berry, Designated Federal Officer, ONC

# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster



Name	Organization	Name	Organization
<b>Hans Buitendijk* (Co-Chair)</b>	<b>Oracle Health</b>	<b>Shelly Spiro (Co-Chair)</b>	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescriptive North Dakota Health Information Network	Ketan Mehta	Micro Merchant Systems
Shila Blend*		Justin Neal	Noble Health Services Dell Medical School, University of Texas at Austin
David Butler	Curatro, LLC Texas Department of State Health Services	Elieil Oliveira*	
Steven Eichner*	MCG Health, part of the Hearst Health network	Naresh Sundar Rajan*	CyncHealth
Rajesh Godavarthi*	Center for Disease Control and Prevention	Scott Robertson	Bear Health Tech Consulting
Adi V. Gundlapalli**		Alexis Snyder*	Individual
Jim Jirjis*	HCA Healthcare	Fillipe Southerland*	Yardi Systems, Inc.
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Community Pharmacy Owner
Steven Lane*	Health Gorilla Department of Veterans Health Affairs	Sheryl Turney*	Elevance Health
Meg Marshall**		Afton Wagner	Walgreens
Anna McCollister*	Individual		

# Agenda

**10:30 AM**

## **Call to Order/Roll Call**

- Mike Berry, Designated Federal Officer, ONC

**10:35 AM**

## **Opening Remarks**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**10:40 AM**

## **SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities**

- RDML (retired) Pamela Schweitzer, Assistant Surgeon General and 10th Chief Pharmacist USPHS
- Lisa Schwartz, Senior Director, Professional Affairs, National Community Pharmacists Association (NCPA)
- Darren Townzen, Senior Director Health and Wellness Billing and Reconciliation, Walmart
- Chad Worz, Executive Director and CEO, American Society of Consultant Pharmacists (ASCP)
- Michael Popovich, CEO and Jason Briscoe, Director of Pharmacy Operations, STC Health

**11:05 AM**

## **Discussion**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**11:50 AM**

## **Public Comment**

- Mike Berry, Designated Federal Officer, ONC

**11:55 AM**

## **Task Force Work Planning**

- Shelly Spiro, Co-Chair
- Hans Buitendijk, Co-Chair

**12:00 PM**

## **Adjourn**



# Opening Remarks

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

**Overarching charge:** Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

**Recommendations Due: November 9, 2023**

## **Specific charge:**

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities
2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
4. Identify policy and technology needs and considerations for direct-to-consumer medication services.



# Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Discussion

## TOPIC 1 (for discussion June 21 and June 28):

### 1. Public Health, Emergency Use Authorizations, and Prescribing Authorities

#### Short-term

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

*(FYI: The following will be discussed at meetings 3 and 4)*

#### Long-term

- a. *Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.*





# SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities

RDML (retired) Pamela Schweitzer, Assistant Surgeon General and 10th Chief Pharmacist USPHS


Lisa Schwartz, Senior Director, Professional Affairs, National Community Pharmacists Association (NCPA)

Darren Townzen, Senior Director Health and Wellness Billing and Reconciliation, Walmart

Chad Worz, Executive Director and CEO, American Society of Consultant Pharmacists (ASCP)

Michael Popovich, CEO and Jason Briscoe, Director of Pharmacy Operations, STC Health





**RDML (retired) Pamela  
Schweitzer, Assistant Surgeon  
General and 10th Chief  
Pharmacist USPHS**

---

# Community-based pharmacy practice needs interoperability

*Testimony to:*

HITAC Task Force on Pharmacy Interoperability and Emerging Therapeutics

Lisa Schwartz, PharmD, RPh, CPC-A  
Senior Director, Professional Affairs



# Health information exchange improves each step in the Pharmacists' Patient Care Process\*

- **Collect** – HIE is preferred for obtaining health data such as medication history and lab reports
- **Assess** – standardized data can be used by automated processes to suggest medication-related problems
- **Plan** – thousands of pharmacies in the CPESN® USA clinically integrated network use the Pharmacist eCare Plan\*\*
- **Implement** – exchange of a care plan promotes patient-centered care, includes a reconciled med list for the patient and other providers, public health reporting, e-prescriptions, remote patient monitoring
- **Follow-up: Monitor & Evaluate** – electronic referral, lab orders, consultation notes, questionnaires, IIS report/query



\* <https://jcpp.net/patient-care-process/>

\*\* <https://www.ecareplaninitiative.com/>



# Case study

JJ, a 52-year-old female, came to the community pharmacy inquiring about its test and treat program after 2 days of mild symptoms typical of COVID-19. The pharmacist reviewed JJ's medication list and after a short interview, a SARS-CoV-2 antigen test resulted positive; Paxlovid was indicated. JJ was unsure of her history of renal or liver disease.

Using HIE the pharmacist was able to look at the patient's renal function. Patient GFR was 65. The pharmacist's access to labs allowed her to help JJ start treatment promptly.

72 hours later, the pharmacist called JJ and learned she felt much better and accepted the recommendation to schedule an appointment for a booster.

---

# Interoperability for test to treat

- **COLLECT**

- Medication list
- Labs: renal and hepatic function; COVID-19 test

- **ASSESS**

- Treatment indicated, drug-drug interaction, RPh EUA conditions

- **PLAN**

- Treatment plan, self-monitoring plan, refer for dose adjustment, refer for other treatment, refer for immediate medical care

- **IMPLEMENT**

- Write Rx, dispense Rx, report COVID-19 test result

- **MONITOR & EVALUATE**

- Drug side effects; refer to PCP, ER when needed; query IIS



---

The *voice* of the  
community pharmacist.

[lschwartz@ncpa.org](mailto:lschwartz@ncpa.org)

[www.ncpa.org](http://www.ncpa.org)

Follow us on social media





**Darren Townzen, Walmart**

# Short Term - Challenges

- What is in pharmacy today?
  - Real-time adjudication/Drug Utilization Review
- What was experienced with the last PHE?
  - Billing complexities that could be distracting from patient care
  - Reduced or no visibility to other vaccine administrations
- What was done?
  - Adaptation – NCPDP Emergency Preparedness Task Group





# Short Term – Lessons learned

- What did we learn?
  - It's not all about pharmacy
  - The downside of not being inside the healthcare's data continuum
  - The need to consume and utilize new data elements such as lab results for test to treat
- What needs to be done?
  - Rethinking pharmacy practice management systems to incorporate interoperability to other systems and providers
  - Operationalizing the process into workflow



# Short Term – Next steps

- What can ONC do?
  - Continued pharmacy and Industry engagement
    - Pharmacist are one of many in the care of a patient
    - The normalization of sharing information
    - Demonstration projects to learn what can be done





**Chad Worz, PharmD, BCGP, FASCP**  
**Chief Executive**  
**ASCP**



## ASCP Overview

### Mission

- “Empowering pharmacists to promote healthy aging through the appropriate use of medications.”


### Vision

- “Achieving safe, effective, and appropriate use of medications by all older adults.”



# Current Pathways for Vaccine Access in Skilled Nursing Facilities (SNFs)

(Process developed by the American Society of Consultant Pharmacists)



\*Facilities and pharmacies may contract for administration services currently under the pharmacy's CDC provider contract.

\*\*Time "catch up/one off" vaccinations with consultant pharmacist visit.

\*\*\*Facility must sign Federal CDC facility sub provider vaccination agreement.

\*\*\*\* 26 states require any entity (including nursing homes) to report vaccine data to IIS system. Reporting entities must apply and be approved to report, and many IIS systems take months to be approved. Most LTC pharmacies are already linked and can report if the vaccination is managed through the blue paths above.

# Pharmacy Interoperability and Emerging Therapeutics

## The Covid Experience – A Network Perspective

HITAC Task Force

June 28, 2023

***STChealth, LLC***

Michael L. Popovich (CEO)

Jason Briscoe (Director of Pharmacy Operations)



# 1. COVID-19 Vaccination Efforts - Numbers

## Pharmacy Pandemic Response – Vaccinations

In the 2009 H1N1  
Pandemic

Pharmacy provided ~  
6 Million H1N1  
Vaccinations

In the 2020 COVID-  
19 Pandemic

Pharmacy provided >  
50x this @ ~302  
Million COVID-19  
Vaccinations

85% of these came across  
STC's National Immunization  
Network on to state and  
jurisdictional Public Health IIS  
and then on to CDC

In 2020 this network  
connected > 56,000  
Pharmacies IIS across the US  
(Interoperable)

## 2. EOP Interoperability Lessons (from ONC Past Initiatives)

### COVID-19 Validated:

- Value of Standards
  - HL7 for Immunization Data Exchange
- Value of Meaningful Use (2015)
  - Interoperable Electronic Data Exchange
  - EHR and Pharmacy Management System Integration (in-workflows)
- Value of Investment in IT Modernization
  - SaaS / Cloud IT – Highly Adaptable in Rapidly Changing Environments

- Value of Public – Private Partnerships
  - Under the CDC and PH Mission Umbrella
- Value of Real or Near Real Data
  - Situational Awareness, Gaps, Policy Support, Epidemiology, ...
- Value of the Consumer
  - Access to their Records, Vaccine IQ and Awareness



# 3. EOP Interoperability Lessons (Barriers)

## COVID Demonstrated:

- Impact of Volumes on Supporting IT
  - Importance of Networks – For Rapid Exchange of Information from the Point of Care to the CDC Data Systems
  - Importance of Processing Systems to Performance Scale (Cloud versus On Premises)
- Impact of Volumes on PH Resources
  - Ability to Rapidly On-board Individual Pharmacies for Data Sharing
- Impact of Emerging Disease Insights and Evolving Vaccine Therapeutics
  - Agile Changes to Supporting Applications, Processes, Data Needs
  - Lack of Connectivity to Other Health Information Systems at POC

## 4. Steps for a New Pharmacy to Insure EOP Readiness + Achieve Successful Day to Day Electronic Data Reporting and Exchange

1. Understand and Determine Your Opportunity (Customer Loyalty, Revenue, Expansion Potential)

- a. Patient-Base Demographics
- b. Area Immunization Gaps and Types
- c. Compliance Reporting (Cost) versus Bidirectional Exchange (Revenue)
- d. Store Target Revenue from Vaccinations

1. Establish Interoperability In Workflow with PMS Integration

3. Initiate PH Onboarding (Link and Data Validation to IIS)

4. Utilize Intelligent Exchange (Bidirectional with Decision Support)

- a. Pharmacy Engagement – Active Immunizers
- b. Patient Engagement
- c. Community Engagement – Marketing
- d. Ecosystem Engagement

5. The Future...  
from  
vaccinations to  
point of care  
testing... from  
therapeutics to  
integrated  
patient care  
and outreach...

What If:

- Jurisdictional and Federal Reporting Expands?
- Test to Treat and/or Assess to Prescribe and Treat Remains Critical?
- New Vaccines Prove to Be Revenue and Relevance Accelerators (RSV)?
- Pharmacy Connectivity is Viewed as an Extension to Public Health Infrastructure (i.e. integrated with CDC's IZ Gateway, Notifiable Disease Reporting)?

COVID Demonstrated Being Interoperable with the Larger Health Care Ecosystem Has a Significant Upside.

Pharmacies Should Connect to Public Health for Immunizations to Create the Foundational Framework, Which Establishes Readiness for the Future.

## 6. What Can ONC Do?

### Request ONC to Open the Door for Pharmacies Interacting with Quality Networks

- Health Records (or segments of) – Diagnosis Codes, Labs, Test Results
  - Example: COVID-19 Therapeutics
- Refined Query on Demand with Quality Network

### Continue w/Standards and IT Modernization Movement, To Increase Interoperability with Existing Systems, Examples:

- Consider a New HIT Meaningful Use Effort: Targets Pharmacy (PMS, LTC PMS & EHRs).
- Help Drive Pharmacy Interoperability Demonstration Projects

### Lead Efforts for Data Use Agreements at Both State PH, Pharmacy and Provider Levels

- Data for Decision Support
- Data for Research
- Data for the Consumer & Integrated Health Care



# Discussion

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair



# Public Comment

To make a comment please  
**Use the Hand Raise Function**

**If you are on the phone only, press “\*9” to raise your hand**

*(Once called upon, press “\*6” to mute/unmute your line)*

**All public comments will be limited to three minutes**

You may also email your public comment to [onc-hitac@accelsolutionsllc.com](mailto:onc-hitac@accelsolutionsllc.com)

*Written comments will not be read at this time,  
but they will be delivered to members of the task force and made part of the public record*




# Task Force Work Planning

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

# Upcoming Meetings



Month	Task Force Meeting Dates	HITAC Meeting Date
July	12, 19, 26	July 13
August	9, 16, 23, 30	August 17 (TF Update)
September	13, 20, 27	September 14 (TF Update)
October	4, 11, 18, 25	October 19 (TF Update)
November	1	November 9 (Final Recommendation and Vote)





**Adjourn**